In HCC, gastric cancer, pancreatic cancer and esophageal cancer, patients with increased SP1 were more likely to have poor outcomes (HR = 1.95; 95% CI: 1.16-3.28; p < 0.05). This evidence concerns the gene SP1 and esophageal cancer.